摘要
耐甲氧西林金黄色葡萄球菌(MRSA)是目前临床上感染严重的耐药性细菌之一,给人类健康造成了巨大威胁。万古霉素为目前治疗MRSA感染的最后一道防线,但耐万古霉素金黄色葡萄球的出现使对治MRSA新型药物的开发迫在眉睫。微生物是巨大的天然化合物宝库,曾为现代抗生素工业提供了多数主力抗生素。新近研究表明,微生物源天然产物有着良好的对治MRSA的生物活性,有些已经被开发为临床治疗MRSA感染的一线药物。本文从MRSA耐药机理,新型MRSA治疗药物研究的意义,到目前常用治疗MRSA的药物,尤其针对来源于微生物拮抗MRSA的天然产物研究进行了综述,并对未来发展趋势进行了展望。
Methicillin-resistant Staphylococcus aureus(MRSA) is one of the major drug-resistant bacterial pathogens which has posed a great threat to human being. Vancomycin is currently the best and the last-resort antibiotic used for the treatment of MRSA infections. The emergence of vancomycin-resistant Staphylococcus aureus has justified the great urgency of the exploration of novel drugs against MRSA. The microbial-derived antimicrobial metabolites had enabled the modern antibiotic-industries and saved millions of lives in the past century. Notably, a panel of promising metabolites were found recently in microbes which demonstrated decent anti-MRSA activity.Some of them have been developed as first-line drugs used in clinic. This review went over the mechanism of MRSA resistance, the importance of the exploration of new MRSA therapeutics, the commonly used therapeutic drugs, as well as the potential natural products of anti-MRSA derived from microorganisms which had been found. Lastly, a perspective was made to cover the trends of the development of anti-MRSA agents of the microbial origin.
作者
薛梅
孙晓雯
刘国瑞
何增国
Xue Mei;Sun Xiao-wen;Liu Guo-rui;He Zeng-guo(Ocean University of China,School of Medicine and Pharmacy,Qingdao 266003;Marine Biomedical Research Insititute of Qingdao,Qingdao 266100;Qingdao Bioantai Biotechnology Co.,Ltd.,Qingdao 266100)
出处
《中国抗生素杂志》
CAS
CSCD
2020年第6期533-539,共7页
Chinese Journal of Antibiotics
基金
青岛市海洋生物医药科技创新中心建设专项(No.2017-CXZX01-5-3)
作者简介
薛梅,女,生于1993年,在读硕士研究生,专业方向为微生物与生化药学,E-mail:13255533197@163.com;通讯作者:何增国,E-mail:bioantai88@vip.163.com
